VALITEST focused directly on validating diagnostic tests for plant health, while EMPHASIS and XF-ACTORS also involved detection methods for pests and Xylella fastidiosa.
ORGANISATION EUROPEENNE ET MEDITERRANEENNE POUR LA PROTECTION DES PLANTES
Intergovernmental plant health organization setting diagnostic standards and pest management policy for 52 Euro-Mediterranean countries.
Their core work
EPPO is the intergovernmental organization responsible for plant health policy and standards across the Euro-Mediterranean region. They develop diagnostic protocols, pest risk assessments, and phytosanitary regulations that member countries adopt into national law. In H2020 projects, they contribute their unique role as the body that validates and standardizes diagnostic tests for regulated plant pests, bridging the gap between research laboratories and official plant health services. Their work directly supports biosecurity by ensuring that detection methods for quarantine organisms are reliable, reproducible, and fit for regulatory use.
What they specialise in
XF-ACTORS targeted early detection, prevention, and disease management strategies for Xylella fastidiosa, one of Europe's most damaging plant pathogens.
EMPHASIS addressed integrated solutions for effective management of pests and harmful alien species threatening European agriculture and ecosystems.
Both VALITEST and INEXTVIR involve NGS technologies applied to plant virus detection, indicating a growing investment in genomics-based diagnostics.
How they've shifted over time
EPPO's early H2020 involvement (2015-2016) centered on specific pest threats — particularly Xylella fastidiosa containment and invasive species management, reflecting the urgent European response to the Xylella crisis in southern Europe. By 2018-2021, their focus shifted decisively toward diagnostic infrastructure: test validation, standardized protocols, proficiency testing, and next-generation sequencing technologies. This evolution mirrors a broader move from reactive pest-specific responses toward building systematic, technology-driven diagnostic capacity across all plant health threats.
EPPO is investing in genomics-based diagnostics and virome analysis, positioning itself as the standards authority for next-generation plant health testing across Europe.
How they like to work
EPPO consistently joins projects as a participant or third-party contributor rather than leading them — they have zero coordinator roles across all four projects. This fits their institutional identity: they are the standards body that validates and harmonizes what research consortia develop. With 76 unique partners across 21 countries, they operate as a high-connectivity node, linking diverse research groups to the regulatory framework their results must ultimately satisfy.
EPPO has collaborated with 76 distinct partners across 21 countries, reflecting their pan-European mandate. Their network spans the full Euro-Mediterranean region, connecting national plant protection agencies, research institutes, and universities across a remarkably broad geographic footprint for just four projects.
What sets them apart
EPPO occupies a role no other organization can replicate: they are the official intergovernmental body that sets plant health diagnostic standards for 52 member countries. Any consortium developing new pest detection methods benefits enormously from EPPO's involvement because it creates a direct pathway from research output to adopted regulatory standard. For businesses developing diagnostic tools or biopesticides, EPPO's endorsement is effectively the market-entry stamp for Europe.
Highlights from their portfolio
- VALITESTTheir largest funded project (EUR 205K), directly aligned with EPPO's core mandate of validating and standardizing diagnostic tests for plant pests across Europe.
- XF-ACTORSPart of Europe's major coordinated response to the Xylella fastidiosa crisis that devastated olive groves in Italy, involving multidisciplinary containment research.
- INEXTVIRSignals EPPO's strategic move into next-generation sequencing and virome analysis through a Marie Curie training network, building future capacity in genomics-based diagnostics.